focus -WSS

focus

author：Wikipedia 2025-10-04 05:22:35 Page View：4829

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say
Next article： New air purifier tech could be key to improving indoor air quality

focus

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

What Henrietta Lacks settlement says about racism in medicine

ApaintingofHenriettaLacksHenriettaLacksHouseofHealingForwhatwouldhavebeenHenriettaLacks’103thbirthda

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

1:03Russia'sDefenseMinistry'sfootageofjointnavaldrillswithChinaintheBeringSea,sharedonAug.4,2023.Rus

focus

explore

focus

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say